REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 (clinicaltrials.gov) - Sep 23, 2025 - P2/3 | N=600 | Terminated | Sponsor: Sutro Biopharma, Inc. | Trial completion date: Feb 2028 ➔ Aug 2025 | Recruiting ➔ Terminated | Trial primary completion date: Aug 2027 ➔ Aug 2025; Due to strategic business considerations, Sutro has deprioritized the development of luveltamab tazevibulin, leading to termination of the REFRaME program. This decision is not related to any safety or efficacy concerns associated with luvelta
Platinum resistant • Trial completion date • Trial primary completion date • Trial termination • Epithelial Ovarian Cancer • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • FOLR1
|